Friday 6 November 2026 Export RYTM’s income statement to Excel — free account

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.

Revenue: +79.6%
EPS: +26.9%
Free cash flow: +95.4%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

112.38 7.36 +7.01%

Follow RYTM

Alert me

Market cap: $7.3B
P/E: 0.0×
Fwd P/E: −31.6×
Dividend yield: —
F-score: 6/9
Altman Z: 15.89
Beneish M: −2.93
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Rhythm Pharmaceuticals, Inc. (RYTM) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Product revenue, net	195 102.64%	130 100.00%	77 100.00%	17 71.43%	3 100.00%
License revenue	(5) (2.64%)	0 0.00%	0 0.00%	7 28.57%	0 0.00%
Revenue	190	130	77	24	3

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022
Single reportable segment	190 100.00%	130 100.00%	77 100.00%	24 100.00%
Revenue	190	130	77	24

Gross profit by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022
Single reportable segment	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡

Revenue by region $m

Line	FY2024	FY2023	FY2022	FY2021
United States	96 73.86%	62 80.62%	21 89.17%	3 100.00%
International	34 26.14%	15 19.38%	3 10.83%	—
Revenue	130	77	24	3

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.